Involvement of TLR2-TLR4, NLRP3, and IL-17 in pain induced by a novel Sprague-Dawley rat model of experimental autoimmune encephalomyelitis.
Level 5 - mechanism / opinion, no new human data
Preclinical animal experiment with no human data
PubMed 36176709 · doi:10.3389/fpain.2022.932530
What was done
Adult male Sprague-Dawley rats were treated with intradermal myelin-oligodendrocyte-glycoprotein (MOG 1-125) at doses of 0, 4, 8, or 16 μg in incomplete Freund's adjuvant to establish a model of experimental autoimmune encephalomyelitis (EAE)-induced pain without confounding motor deficits. Mechanical allodynia (via von Frey testing) and motor disability were assessed weekly for up to 1 month. To investigate mechanisms, rats with established allodynia received subcutaneous (+)-naltrexone (a TLR2/TLR4 antagonist) daily for 13 days or intrathecal injections of MCC950 (an NLRP3 antagonist) or an IL-17 neutralizing antibody. Spinal glial immunoreactivity and demyelination were also evaluated.
What was found
MOG doses of 8 and 16 μg produced stable mechanical allodynia lasting up to 1 month without hindpaw motor impairment, but exact numerical values, group sizes, and effect sizes were not reported in the abstract. Daily subcutaneous (+)-naltrexone reversed the mechanical allodynia and attenuated spinal glial immunoreactivity. Acute intrathecal administration of either MCC950 or anti-IL-17 antibody also reversed EAE-induced pain. In addition, spinal demyelination correlated with the severity of motor deficits.
Why it matters
This study establishes a low-dose rat model that isolates MS-related neuropathic pain from confounding motor paralysis, identifying TLR2/4, NLRP3 inflammasomes, and IL-17 as potential therapeutic targets for pain management in multiple sclerosis.
Limits
The abstract does not report specific sample sizes, effect sizes, or quantitative statistical values. The investigation was restricted to adult male rats, precluding assessment of sex differences in a disease known for female predominance in humans. As a preclinical animal model, direct clinical translation to human multiple sclerosis pain remains unverified.
Cited by
- context Low-dose naltrexone inhibits the NLRP3 inflammasome pathway.